key: cord-0850431-k3d7fzt4 authors: Chao, Chien-Ming; Lai, Chih-Cheng; Yu, Wen-Liang title: COVID-19 associated mucormycosis – an emerging threat date: 2022-01-13 journal: J Microbiol Immunol Infect DOI: 10.1016/j.jmii.2021.12.007 sha: 1ee8e47cec70ebe7138ae4430f715c453efbf46f doc_id: 850431 cord_uid: k3d7fzt4 Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations. Coronavirus disease 2019 caused by severe acute respiratory syndrome 23 coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in 24 the end of 2019. 1 As of November 20, 2021, more than 255 million confirmed cases 25 have been identified worldwide and more than 5 million deaths have been reported. 1 spp. [5] [6] [7] [8] [9] [10] In addition to these co-pathogens, many cases of mucormycosis among 37 COVID-19 patients have been reported recently. [11] [12] [13] [14] [15] [16] [17] [18] Mucormycosis is a rare but 38 aggressive fungal disease and it mainly affects patients with poorly controlled diabetes 39 mellitus and severely immunocompromised patients. 19 In contrast to aspergillosis, 40 J o u r n a l P r e -p r o o f of serum would reduce the capacity of transferrin to bind iron, thus offering the 80 unbound iron in the DKA serum to support the profuse growth of R. oryzae. DKA sera 81 did not support fungal growth at two conditions of either iron-deficient status or at a 82 serum pH greater than or equal to 7.4. 55 These BHB-developed acidotic serum conditions extremely predispose to 95 mucormycosis, but not to aspergillosis. [60] [61] [62] care. 64 The combination of steroid therapy and diabetes mellitus can augment 105 immunosuppression and hyperglycemia, increasing the risk of mucormycosis. 64 Most 106 cases were reported from India in the literature. 41 Even though a rather high regional 107 prevalence in India, a 2.1-fold rise in mucormycosis during the COVID-19 pandemic 108 than previous year was noted. 13 The median time interval between COVID-19 diagnosis 109 and the first evidence of a mucormycosis infection was 7 -15 days. 38,63 110 Cases of mucormycosis may occur in COVID-19 patients without diabetes 111 mellitus and only with mild-to-moderate diseases outside intensive care units, as 112 reported in the Netherlands. 11 Although severe or critical COVID-19 in poorly 113 controlled diabetic patients is the most perfect storm for mucormycosis, 65 diabetes mellitus was presented in 78% of 2,826 patients, and 87% had been treated 141 with corticosteroid. 38 Another study of 187 CAM cases showed the similar thing that 142 78.1% of patients had received corticosteroid and 60.4% of patients had diabetes 143 mellitus. 13 However, COVID-19 could be the only underlying disease in 32.6% of 144 CAM patients. 13 The most common involved site of CAM was rhino-orbital cerebral, 145 but lung, kidney, cutaneous, stomach, mediastinal lymph node, heart, pericardium, 146 kidney, musculoskeletal and disseminated infections have been reported (Table 147 1). 13, 38, 69, 70 For patients with rhino-orbital-cerebral sinusitis, orbital/facial pain and 148 orbital/facial edema were the most common symptoms, followed by loss of vision, 149 ptosis and nasal block. 38 Additionally, these patients could have the presentation of 150 fever, eyelid edema, conjunctival chemosis, deteriorating visual acuity, proptosis, 151 ophthalmoplegia, diplopia, periorbital pain, orbital/facial discoloration, cranial nerve 152 palsy, headache, nasal blockage, ear pain, black nasal crusts, nasal discharge, periocular 153 hypoesthesia, palatal ulcer/eschar, toothache, loose teeth, epistaxis, and facial 154 deviation/palsy. 12 of Mucorales were evaluated, more isolates were found to be potentially susceptible to 191 isavuconazole when compared to posaconazole. 81 Successful treatment of fungal 192 meningitis with isavuconazole in limited case reports supports brain penetration in 193 humans. 82 In addition to appropriate antifungal agents, the management of 194 mucormycosis is multimodal, including reversal of underlying risk factors, such as 195 glycemic control, and extensive or repeated surgical debridement. 72 The morbidity and mortality of CAM remain high. 23 Buil et al. reported that three of 4 201 CAM cases developed in the ICU and three deaths occurred in the Netherlands. 11 In a 202 series of 187 CAM cases in India, the reported overall mortality was 37.4% (70/187) 203 and 44.1% (75/170) within 6 and 12 weeks respectively. 13 The mortality rates were 204 substantially higher in non-prevalent regions (> 50% to 100% in United States and the 205 European countries) than prevalent regions (about 40% to 50% in the middle East and 206 Egypt) and lowest (13%) in India (Table 1) . However, the prognosis of mucormycosis 207 could vary according to the site of involvement. 13 The largest study of 2,826 patients 208 with COVID-19 associated rhino-orbital-cerebral mucormycosis in India reported the 209 all-cause mortality was 14% (n = 305) of 2,128 patients with available outcome data. 38 J o u r n a l P r e -p r o o f Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths Extra-respiratory manifestations of COVID-19 Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? First COVID-19 mortality case in Taiwan with bacterial co-infection by national surveillance of critically ill patients with influenza-negative pneumonia Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis Coinfections with bacteria, fungi, and respiratory viruses in patients with SARS-CoV-2: A systematic review and meta-analysis Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis COVID-19 associated with pulmonary aspergillosis: A literature review Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicenter study from Iran Multicenter epidemiologic study of coronavirus disease-associated mucormycosis Mucormycosis-A dreaded complication Of Covid-19 Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19) Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient -Case report and review of literature Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia Infections Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts Severe gastric mycormycosisinfection followed by cytomegalovirus pneumonia in a renal transplant recipient: A case report and concise review of the literature Fatal systemic adenoviral infection superimposed on pulmonary mucormycosis in a child with acute leukemia: A case report Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: A case report Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia Rhino-orbital mucormycosis associated with COVID-19 A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: A case series and a review of literature Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations Mucormycosis associated with COVID-19 in two kidney transplant patients Rhinoorbital mucormycosis during steroid therapy in COVID-19 patients: A case report Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy Mucormycosis with orbital compartment syndrome in a patient with COVID-19 A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19 Rhinocerebral mucormycosis and COVID-19 pneumonia Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2,826 patients in India -Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature SARS-CoV-2, Uncontrolled diabetes and corticosteroids-An unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis Orbital infarction syndrome secondary to rhinoorbital mucormycosis in a case of COVID-19: Clinico-radiological features COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? Maxillofacial infections in Covid-19 eraactuality or the unforeseen: 2 Case reports Paranasal mucormycosis in COVID-19 patient COVID-19 and orbital mucormycosis Mucormycosis in post-COVID-19 renal transplant patients: A lethal complication in follow-up Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India Rise of the phoenix: Mucormycosis in COVID-19 times Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum CT and MRI findings of invasive mucormycosis in the setting of COVID-19: Experience from a single center in India Sino-orbital mucormycosis in a COVID-19 patient: A case report Mucor in a viral land: A tale of two pathogens Mucormycosis in India: unique features A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis Host-iron assimilation: pathogenesis and novel therapies of mucormycosis CotH3 mediates fungal invasion of host cells during mucormycosis GRP78 and integrins play different roles in host cell invasion during mucormycosis COVID19 associated mucormycosis: Is GRP78 a possible link? Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India COVID-19-associated mucormycosis: An updated systematic review of literature The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis The environmental source of emerging Apophysomyces variabilis infection in India The ecology of the Zygomycetes and its impact on environmental exposure A fatal case of Rhizopus azygosporus pneumonia following COVID-19 Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19 Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection Epidemiology and outcome of zygomycosis: a review of 929 reported cases Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient Pulmonary aspergillosis and mucormycosis in a patient with COVID-19 ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low-and middleincome countries Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium Mucormycosis medications: a patent review Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement Isavuconazole: A promising salvage therapy for invasive mucormycosis Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order Mechanism of action, clinical efficacy, and resistance Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19